JP2020524994A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020524994A5 JP2020524994A5 JP2019568660A JP2019568660A JP2020524994A5 JP 2020524994 A5 JP2020524994 A5 JP 2020524994A5 JP 2019568660 A JP2019568660 A JP 2019568660A JP 2019568660 A JP2019568660 A JP 2019568660A JP 2020524994 A5 JP2020524994 A5 JP 2020524994A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- zfns
- called
- gene
- zfn
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims description 86
- 108010017070 Zinc Finger Nucleases Proteins 0.000 claims description 81
- 108091033319 polynucleotide Proteins 0.000 claims description 34
- 102000040430 polynucleotide Human genes 0.000 claims description 34
- 239000002157 polynucleotide Substances 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 22
- 238000012986 modification Methods 0.000 claims description 20
- 230000004048 modification Effects 0.000 claims description 20
- 108091008874 T cell receptors Proteins 0.000 claims description 16
- 238000010362 genome editing Methods 0.000 claims description 16
- 238000012239 gene modification Methods 0.000 claims description 14
- 101150076800 B2M gene Proteins 0.000 claims description 10
- 210000000130 stem cell Anatomy 0.000 claims description 10
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 8
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 8
- 108700019146 Transgenes Proteins 0.000 claims description 8
- 238000012217 deletion Methods 0.000 claims description 8
- 230000037430 deletion Effects 0.000 claims description 8
- 108020001507 fusion proteins Proteins 0.000 claims description 8
- 102000037865 fusion proteins Human genes 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 238000003780 insertion Methods 0.000 claims description 5
- 230000037431 insertion Effects 0.000 claims description 5
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 4
- 101150118346 HLA-A gene Proteins 0.000 claims description 4
- 101150000578 HLA-B gene Proteins 0.000 claims description 4
- 101150035071 HLA-C gene Proteins 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 102000015736 beta 2-Microglobulin Human genes 0.000 claims description 4
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 238000003776 cleavage reaction Methods 0.000 claims description 4
- 210000005260 human cell Anatomy 0.000 claims description 4
- 230000007017 scission Effects 0.000 claims description 4
- 101150095542 tap gene Proteins 0.000 claims description 4
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 101150043532 CISH gene Proteins 0.000 claims description 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 2
- 210000003162 effector t lymphocyte Anatomy 0.000 claims description 2
- 208000024908 graft versus host disease Diseases 0.000 claims description 2
- 108020004999 messenger RNA Proteins 0.000 claims description 2
- 210000003289 regulatory T cell Anatomy 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 13
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022137773A JP7482176B2 (ja) | 2017-06-16 | 2022-08-31 | Ｔ細胞および／またはｈｌａ受容体の標的化破壊 |
| JP2024017157A JP2024036610A (ja) | 2017-06-16 | 2024-02-07 | Ｔ細胞および／またはｈｌａ受容体の標的化破壊 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762521132P | 2017-06-16 | 2017-06-16 | |
| US62/521,132 | 2017-06-16 | ||
| US201762542052P | 2017-08-07 | 2017-08-07 | |
| US62/542,052 | 2017-08-07 | ||
| US201762573956P | 2017-10-18 | 2017-10-18 | |
| US62/573,956 | 2017-10-18 | ||
| PCT/US2018/037844 WO2018232296A1 (en) | 2017-06-16 | 2018-06-15 | Targeted disruption of t cell and/or hla receptors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022137773A Division JP7482176B2 (ja) | 2017-06-16 | 2022-08-31 | Ｔ細胞および／またはｈｌａ受容体の標的化破壊 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020524994A JP2020524994A (ja) | 2020-08-27 |
| JP2020524994A5 true JP2020524994A5 (enExample) | 2021-06-17 |
| JP7419073B2 JP7419073B2 (ja) | 2024-01-22 |
Family
ID=64656803
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019568660A Active JP7419073B2 (ja) | 2017-06-16 | 2018-06-15 | Ｔ細胞および／またはｈｌａ受容体の標的化破壊 |
| JP2022137773A Active JP7482176B2 (ja) | 2017-06-16 | 2022-08-31 | Ｔ細胞および／またはｈｌａ受容体の標的化破壊 |
| JP2024017157A Pending JP2024036610A (ja) | 2017-06-16 | 2024-02-07 | Ｔ細胞および／またはｈｌａ受容体の標的化破壊 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022137773A Active JP7482176B2 (ja) | 2017-06-16 | 2022-08-31 | Ｔ細胞および／またはｈｌａ受容体の標的化破壊 |
| JP2024017157A Pending JP2024036610A (ja) | 2017-06-16 | 2024-02-07 | Ｔ細胞および／またはｈｌａ受容体の標的化破壊 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230295563A1 (enExample) |
| EP (1) | EP3638783A4 (enExample) |
| JP (3) | JP7419073B2 (enExample) |
| KR (1) | KR102708624B1 (enExample) |
| CN (1) | CN110997913B (enExample) |
| AU (1) | AU2018283310B2 (enExample) |
| BR (1) | BR112019026622A2 (enExample) |
| CA (1) | CA3066641A1 (enExample) |
| IL (1) | IL271298A (enExample) |
| SG (1) | SG11201911729SA (enExample) |
| WO (1) | WO2018232296A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3573464A4 (en) * | 2017-01-26 | 2020-12-30 | Sangamo Therapeutics, Inc. | B CELL ENGINEERING |
| WO2020061161A1 (en) * | 2018-09-18 | 2020-03-26 | Sangamo Therapeutics, Inc. | Programmed cell death 1 (pd1) specific nucleases |
| CN116323921A (zh) | 2020-10-28 | 2023-06-23 | 桑格摩生物治疗股份有限公司 | 从人多能干细胞生成cd4+效应t细胞和调节性t细胞 |
| CN113846070B (zh) * | 2021-10-18 | 2023-05-16 | 翌圣生物科技(上海)股份有限公司 | 高活性的mTET2酶突变体、其编码DNA及其应用 |
| CN118813625B (zh) * | 2024-06-17 | 2025-08-26 | 天海元祺生物科技(天津)有限公司 | 高度靶向人类HLA-A基因的sgRNA及应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004235395A1 (en) * | 2003-04-29 | 2004-11-11 | Wyeth | Methods for prognosis and treatment of solid tumors |
| CA2721372A1 (en) * | 2008-04-21 | 2009-10-29 | Danziger Innovations Ltd. | Plant viral expression vectors and use of same for generating genotypic variations in plant genomes |
| EP2686417B1 (de) * | 2011-03-17 | 2016-06-08 | Miltenyi Biotec GmbH | Tcralpha/beta-depletierte zellpräparationen |
| WO2012127464A2 (en) * | 2011-03-23 | 2012-09-27 | Gavish-Galilee Bio Applications Ltd | Constitutively activated t cells for use in adoptive cell therapy |
| WO2015031619A1 (en) * | 2013-08-28 | 2015-03-05 | Sangamo Biosciences, Inc. | Compositions for linking dna-binding domains and cleavage domains |
| ES2782125T3 (es) * | 2014-03-11 | 2020-09-10 | Cellectis | Método para generar linfocitos T compatibles para trasplante alogénico |
| BR112016025519A2 (pt) * | 2014-05-01 | 2018-01-16 | Univ Washington | engenharia genética in vivo com vetores de adenovírus |
| WO2017011519A1 (en) * | 2015-07-13 | 2017-01-19 | Sangamo Biosciences, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
| CN108699132B (zh) * | 2015-12-18 | 2023-08-11 | 桑格摩生物治疗股份有限公司 | Mhc细胞受体的靶向破坏 |
| ES2983043T3 (es) * | 2015-12-18 | 2024-10-21 | Sangamo Therapeutics Inc | Alteración dirigida del receptor de células T |
| MX2020001594A (es) * | 2017-08-08 | 2020-12-09 | Sangamo Therapeutics Inc | Direccionamiento celular mediado por receptor de antigeno quimerico. |
| JP7275152B2 (ja) * | 2018-02-08 | 2023-05-17 | サンガモ セラピューティクス， インコーポレイテッド | 操作された標的特異的なヌクレアーゼ |
-
2018
- 2018-06-15 WO PCT/US2018/037844 patent/WO2018232296A1/en not_active Ceased
- 2018-06-15 AU AU2018283310A patent/AU2018283310B2/en not_active Expired - Fee Related
- 2018-06-15 BR BR112019026622-4A patent/BR112019026622A2/pt not_active IP Right Cessation
- 2018-06-15 CA CA3066641A patent/CA3066641A1/en active Pending
- 2018-06-15 JP JP2019568660A patent/JP7419073B2/ja active Active
- 2018-06-15 CN CN201880052991.4A patent/CN110997913B/zh active Active
- 2018-06-15 EP EP18818351.1A patent/EP3638783A4/en active Pending
- 2018-06-15 KR KR1020207000964A patent/KR102708624B1/ko active Active
- 2018-06-15 SG SG11201911729SA patent/SG11201911729SA/en unknown
-
2019
- 2019-12-10 IL IL271298A patent/IL271298A/en unknown
-
2022
- 2022-08-31 JP JP2022137773A patent/JP7482176B2/ja active Active
- 2022-10-21 US US17/971,071 patent/US20230295563A1/en active Pending
-
2024
- 2024-02-07 JP JP2024017157A patent/JP2024036610A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020524994A5 (enExample) | ||
| JP7396783B2 (ja) | 移植を改善するためのｃｒｉｓｐｒ／ｃａｓ関連方法および組成物 | |
| Zemmour et al. | Flicr, a long noncoding RNA, modulates Foxp3 expression and autoimmunity | |
| JP2019517803A5 (enExample) | ||
| Peggs et al. | Reduced‐intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long‐term outcomes | |
| Youngblood et al. | Acquired transcriptional programming in functional and exhausted virus-specific CD8 T cells | |
| JP2021502085A5 (enExample) | ||
| JP2018532428A5 (enExample) | ||
| Stavnezer et al. | Differential expression of APE1 and APE2 in germinal centers promotes error-prone repair and A: T mutations during somatic hypermutation | |
| MY185961A (en) | Methods and compositions for gene editing in hematopoietic stem cells | |
| Linscheid et al. | Minor histocompatibility antigens and the maternal immune response to the fetus during pregnancy | |
| NZ743429A (en) | Targeted disruption of the mhc cell receptor | |
| EP4219725A3 (en) | Altering gene expression in modified t cells and uses thereof | |
| JP2018500006A5 (enExample) | ||
| JP2024177252A (ja) | カルボジイミドで処理された寛容化ワクチンによる移植寛容誘導 | |
| Fiorini et al. | Dysfunctional telomeres and hematological disorders | |
| FI3169778T3 (fi) | Ituradan soluja ablatoiva nanos-geeninpoisto | |
| Chen | Efficient gene editing in primary human T cells | |
| Sin et al. | Transplantation of gene-edited hepatocyte-like cells modestly improves survival of arginase-1-deficient mice | |
| Kim et al. | Generation of hypoimmunogenic universal iPS cells through HLA-type gene knockout | |
| Zheng et al. | Expression of tissue‐specific autoantigens in the hematopoietic cells leads to activation‐induced cell death of autoreactive T cells in the secondary lymphoid organs | |
| Kochat et al. | JMJD3 aids in reprogramming of bone marrow progenitor cells to hepatic phenotype through epigenetic activation of hepatic transcription factors | |
| Hoff et al. | Recipient HLA-C haplotypes and microRNA 148a/b binding sites have no impact on allogeneic hematopoietic cell transplantation outcomes | |
| Beck‐Engeser et al. | APOBEC3 enzymes restrict marginal zone B cells | |
| JP2019531754A5 (enExample) |